Gene editing shows clinical wins

Before these trials, the basic idea sounded almost too neat: take a patient’s own blood-making stem cells, edit the DNA in the lab, and put the cells back so the body starts making healthier red blood cells. (fda.gov) The trick is not to build a brand-new blood system from scratch. It is to switch back on fetal hemoglobin, a version of hemoglobin that babies use before birth and that can stand in for the broken adult version in some blood disorders. (casgevy.com) Fetal hemoglobin is like keeping an older backup engine in the car. After birth, the body normally shuts that engine down, but researchers have learned that patients can do much better if they turn some of it back on. (casgevy.com) That matters in sickle cell disease because the damaged adult hemoglobin makes red blood cells turn rigid and crescent-shaped, which can block blood flow and trigger extreme pain crises. Cleveland Clinic reported that a new edited-cell therapy pushed average fetal hemoglobin to 48.1% in treated patients. (newsroom.clevelandclinic.org) It matters in beta thalassaemia because patients cannot make enough working beta-globin, which leaves them anemic and often dependent on regular transfusions. A Nature paper published on April 9, 2026 reported that five patients given a base-edited cell therapy called CS-101 achieved early and durable transfusion independence. (nature.com) Base editing is a more precise version of gene editing. Instead of cutting both strands of DNA like scissors, it changes a single DNA letter more like a pencil erasing and rewriting one character. (nature.com) In the beta thalassaemia trial, researchers edited the control switches for two fetal-globin genes called HBG1 and HBG2. That blocked a protein called BCL11A from keeping fetal hemoglobin turned off. (nature.com) A separate New England Journal of Medicine report described the RUBY trial in severe sickle cell disease using renizgamglogene autogedtemcel, or reni-cel. In 27 of 28 patients, no vaso-occlusive crises occurred after infusion during the reported follow-up period, while one patient had two severe events. (nejm.org) By month 6 in that sickle cell trial, mean total hemoglobin rose to 13.8 grams per deciliter from 9.8 at baseline. The same report said fetal hemoglobin rose from 2.5% before treatment to 48.1% and stayed at or above that level afterward. (nejm.org) This is not the first time doctors have used gene editing against these diseases. The United States Food and Drug Administration already approved Casgevy in December 2023 for sickle cell disease and later expanded approval to transfusion-dependent beta thalassemia, both for patients age 12 and older. (fda.gov) (casgevyhcp.com) What is changing now is the level of proof and the range of tools. One approved program uses Clustered Regularly Interspaced Short Palindromic Repeats, or CRISPR, with the Cas9 enzyme, while the newer reports add Cas12a editing in sickle cell disease and base editing in beta thalassaemia. (fda.gov) (nejm.org) (nature.com) The hard part is that these are not simple injections. Patients must first have stem cells collected, then receive high-dose chemotherapy to clear space in the bone marrow, and then wait for the edited cells to grow back into a working blood system. (fda.gov) The access gap is already visible. AJMC reported on February 17, 2026 that racial disparities, cost barriers, and limited treatment infrastructure are still shaping who can realistically get these therapies, especially in sickle cell disease, which affects about 100,000 people in the United States and disproportionately affects Black patients. (ajmc.com) (hematology.org) So the story is no longer whether gene editing can work in blood disorders. The story is that it is working in real patients, with real numbers, and the next fight is over who gets a hospital bed, a transplant team, and a shot at the cure. (nature.com) (nejm.org) (ajmc.com)